骨唾液酸蛋白在恶性肿瘤中的研究进展

doi:10.3760/cma.j.issn.1007-1245.2023.14.004

国际医药卫生导报 ›› 2023, Vol. 29 ›› Issue (14): 1940-1943.DOI: 10.3760/cma.j.issn.1007-1245.2023.14.004

骨唾液酸蛋白在恶性肿瘤中的研究进展

李振连¹ 康小玲² 李辉斌² 廖燕霞² 彭大云¹ 郜红艺²

¹广东祈福医院病理科，广州　511495；²广东省妇幼保健院病理科，广州　511442

收稿日期:2023-02-14 出版日期:2023-07-15 发布日期:2023-07-28
通讯作者: 郜红艺，Email：1522712335@qq.com
基金资助:
广东省医学科学技术研究基金项目（B2022170）

Research progress of bone sialogin in malignant tumors

Li Zhenlian¹, Kang Xiaoling², Li Huibin², Liao Yanxia², Peng Dayun¹, Gao Hongyi²

¹Department of Pathology, Guangdong Clifford Hospital, Guangzhou 511495, China; ²Department of Pathology, Guangdong Women's and Children's Hospital, Guangzhou 511442, China

Received:2023-02-14 Online:2023-07-15 Published:2023-07-28
Contact: Gao Hongyi, Email: 1522712335@qq.com
Supported by:
Project of Medical Science and Technology Research Foundation in Guangdong Province (B2022170)

摘要/Abstract

摘要：

骨唾液酸蛋白（BSP）是由骨基质和肿瘤细胞分泌，存在于细胞外基质（ECM）中的一种非胶原磷酸化糖蛋白，通过与整合素avβ3结合，可以介导肿瘤细胞与ECM的黏附作用、促进ECM的降解、参与血管生成和体液免疫等，在恶性肿瘤增殖、侵袭和转移过程中起着关键作用，被认为是一种新的肿瘤标志物。本文概述了BSP的生物学特性及近年来BSP与恶性肿瘤的相关性研究，进而评估其在恶性肿瘤早期诊断、疗效评价和预后监测的临床意义。

关键词:

恶性肿瘤, 骨唾液酸蛋白, 整合素avβ3, 进展

Abstract:

Bone sialoprotein (BSP) is a non-collagenous phosphorylated glycoprotein secreted by bone matrix and tumor cells, and exists in extracellular matrix (ECM). By binding to integrin avβ3, it can mediate the adhesion between tumor cells and ECM, promote the degradation of ECM, participate in angiogenesis and humoral immunity, etc. It plays a key role in the process of malignant tumor proliferation, invasion, and metastasis, and is considered as a new tumor marker. This paper summarizes the biological characteristics of BSP and the recent studies on the correlation between BSP and malignant tumors, and evaluates the clinical significance of BSP in the early diagnosis, efficacy evaluation, and prognosis monitoring of malignant tumors.

Key words:

Malignant tumors, Bone sialoprotein, Integrin avβ3, Progress

李振连康小玲李辉斌廖燕霞彭大云郜红艺.

骨唾液酸蛋白在恶性肿瘤中的研究进展 [J]. 国际医药卫生导报, 2023, 29(14): 1940-1943.

Li Zhenlian, Kang Xiaoling, Li Huibin, Liao Yanxia, Peng Dayun, Gao Hongyi.

Research progress of bone sialogin in malignant tumors [J]. International Medicine and Health Guidance News, 2023, 29(14): 1940-1943.

参考文献

[1] Bellahcène A,Castronovo V,Ogbureke KU,et al.Small integrin-binding ligand N-linked glycoproteins (SIBLINGs): multifunctional proteins in cancer[J].Nat Rev Cancer,2008,8(3):212-226.DOI:10.1038/nrc2345.
[2] Keller F,Bruch R,Clauder F,et al.Extracellular matrix components regulate bone sialoprotein expression in MDA-MB-231 breast cancer cells[J].Cells,2021,10(6):1304.DOI:10.3390/cells10061304.
[3] Wang L,Song L,Li J,et al.Bone sialoprotein-αvβ3 integrin axis promotes breast cancer metastasis to the bone[J].Cancer Sci,2019,110(10):3157-3172.DOI:10.1111/cas.14172.
[4] Liu B,Xu M,Guo Z,et al.Interleukin-8 promotes prostate cancer bone metastasis through upregulation of bone sialoprotein[J].Oncol Lett,2019,17(5):4607-4613.DOI:10.3892/ol.2019.10138.
[5] Maaroufi A,Khadem-Ansari MH,Khalkhali HR,et al.Serum levels of bone sialoprotein, osteopontin, and β2-microglobulin in stage I of multiple myeloma[J].J Cancer Res Ther,2020,16(1):98-101.DOI:10.4103/jcrt.JCRT_666_16.
[6] Chen Y,Qin Y,Dai M,et al.IBSP, a potential recurrence biomarker, promotes the progression of colorectal cancer via Fyn/β-catenin signaling pathway[J].Cancer Med,2021,10(12):4030-4045.DOI:10.1002/cam4.3959.
[7] Xu T,Qin R,Zhou J,et al.High bone sialoprotein (BSP) expression correlates with increased tumor grade and predicts a poorer prognosis of high-grade glioma patients[J].PLoS One,2012,7(10):e48415.DOI:10.1371/journal.pone.
[8] Wu G,Guo JJ,Ma ZY,et al.Correlation between calcification and bone sialoprotein and osteopontin in papillary thyroid carcinoma[J].Int J Clin Exp Pathol,2015,8(2):2010-2017.
[9] Wang M,Liu B,Li D,et al.Upregulation of IBSP expression predicts poor prognosis in patients with esophageal squamous cell carcinoma[J].Front Oncol,2019,9:1117.DOI:10.3389/fonc.2019.01117.
[10] He JJ,Zhi K,Liu GF.Predictive value of serum bone sialoprotein in patients with bone metastasis of non-small cell lung cancer[J].Onkologie,2011,34(11):584-588.DOI:10.1159/000334058.
[11] Loosen SH,Hoening P,Puethe N,et al.Elevated serum levels of bone sialoprotein (BSP) predict long-term mortality in patients with pancreatic adenocarcinoma[J].Sci Rep,2019,9(1):1489.DOI:10.1038/s41598-018-38352-2.
[12] Lamour V,Nokin MJ,Henry A,et al.Les protéines SIBLING - Outils moléculaires de la progression tumorale et de l'angiogenèse [SIBLING proteins: molecular tools for tumor progression and angiogenesis][J].Med Sci (Paris),2013,29(11):1018-1025.DOI:10.1051/medsci/20132911019.
[13] Ganss B,Kim RH,Sodek J.Bone sialoprotein[J].Crit Rev Oral Biol Med,1999,10(1):79-98.DOI:10.1177/10454411990100010401.
[14] Xu L,Zhang Z,Sun X,et al.Glycosylation status of bone sialoprotein and its role in mineralization[J].Exp Cell Res,2017,360(2):413-420.DOI:10.1016/j.yexcr.2017.09.034.
[15] Bellahcène A,Bonjean K,Fohr B,et al.Bone sialoprotein mediates human endothelial cell attachment and migration and promotes angiogenesis[J].Circ Res,2000,86(8):885-891.DOI:10.1161/01.res.86.8.885.
[16] Muruganandan S,Ionescu AM,Sinal CJ.At the crossroads of the adipocyte and osteoclast differentiation programs: future therapeutic perspectives[J].Int J Mol Sci,2020,21(7):2277.DOI:10.3390/ijms21072277.
[17] Hanahan D.Hallmarks of cancer: new dimensions[J].Cancer Discov,2022,12(1):31-46.DOI:10.1158/2159-8290.CD-21-1059.
[18] Hanahan D,Weinberg RA.Hallmarks of cancer: the next generation[J].Cell,2011,144(5):646-674.DOI:10.1016/j.cell.2011.02.013.
[19] Liu W,Deng Y,Li Z,et al.Cancer evo-dev: a theory of inflammation-induced oncogenesis[J].Front Immunol,2021,12:768098.DOI:10.3389/fimmu.2021.768098.
[20] Sökeland G,Schumacher U.The functional role of integrins during intra- and extravasation within the metastatic cascade[J].Mol Cancer,2019,18(1):12.DOI:10.1186/s12943-018-0937-3.
[21] Wu JS,Jiang J,Chen BJ,et al.Plasticity of cancer cell invasion: patterns and mechanisms[J].Transl Oncol,2021,14(1):100899.DOI:10.1016/j.tranon.2020.100899.
[22] Anunobi CC,Koli K,Saxena G,et al.Expression of the SIBLINGs and their MMP partners in human benign and malignant prostate neoplasms[J].Oncotarget,2016,7(30):48038-48049.DOI:10.18632/oncotarget.10110.
[23] Rivera LB,Bergers G.Intertwined regulation of angiogenesis and immunity by myeloid cells[J].Trends Immunol,2015,36(4):240-249.DOI:10.1016/j.it.2015.02.005.
[24] Strilic B,Offermanns S.Intravascular survival and extravasation of tumor cells[J].Cancer Cell,2017,32(3):282-293.DOI:10.1016/j.ccell.2017.07.001.
[25] El-Kenawi A,Hänggi K,Ruffell B.The immune microenvironment and cancer metastasis[J].Cold Spring Harb Perspect Med,2020,10(4):a037424.DOI:10.1101/cshperspect.a037424.
[26] Nam JS,Suchar AM,Kang MJ,et al.Bone sialoprotein mediates the tumor cell-targeted prometastatic activity of transforming growth factor beta in a mouse model of breast cancer[J].Cancer Res,2006,66(12):6327-6335.DOI:10.1158/0008-5472.CAN-06-0068.
[27] López-Soto A,Gonzalez S,Smyth MJ,et al.Control of metastasis by NK cells[J].Cancer Cell,2017,32(2):135-154.DOI:10.1016/j.ccell.2017.06.009.
[28] Bellahcène A,Merville MP,Castronovo V.Expression of bone sialoprotein, a bone matrix protein, in human breast cancer[J].Cancer Res,1994,54(11):2823-2826.
[29] Hardy E,Fernandez-Patron C.Destroy to rebuild: the connection between bone tissue remodeling and matrix metalloproteinases[J].Front Physiol,2020,11:47.DOI:10.3389/fphys.2020.00047.
[30] Woitge HW,Pecherstorfer M,Horn E,et al.Serum bone sialoprotein as a marker of tumour burden and neoplastic bone involvement and as a prognostic factor in multiple myeloma[J].Br J Cancer,2001,84(3):344-351.DOI:10.1054/bjoc.2000.1614.
[31] Fares J,Fares MY,Khachfe HH,et al.Molecular principles of metastasis: a hallmark of cancer revisited[J].Signal Transduct Target Ther,2020,5(1):28.DOI:10.1038/s41392-020-0134-x.

骨唾液酸蛋白在恶性肿瘤中的研究进展

Research progress of bone sialogin in malignant tumors

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	刘玉姣王超刘菲. 中西医结合治疗产后盆底肌筋膜疼痛的研究进展 [J]. 国际医药卫生导报, 2023, 29(9): 1204-1207.
[2]	王泽川黄月琴. 急性髓系白血病靶向药物治疗新进展 [J]. 国际医药卫生导报, 2023, 29(8): 1045-1048.
[3]	徐仕杰罗泽斌陈晓东. CT肺动脉成像在肺栓塞诊治中的应用进展 [J]. 国际医药卫生导报, 2023, 29(8): 1053-1056.
[4]	张衡潘广涛殷鸣张平尹霞. 自体脂肪移植在整形外科中的研究进展 [J]. 国际医药卫生导报, 2023, 29(7): 889-892.
[5]	吴雪梅张玉杰解胜华. 银屑病与心血管共病关系的研究进展 [J]. 国际医药卫生导报, 2023, 29(4): 453-456.
[6]	杨丽娜王玉夏铂. 烙灸临床应用研究进展 [J]. 国际医药卫生导报, 2023, 29(2): 154-.
[7]	徐希李向阳张波向远刚阳攀张振声许传亮. 预防膀胱癌患者发生静脉血栓栓塞的研究进展 [J]. 国际医药卫生导报, 2023, 29(15): 2073-2076.
[8]	赵嘉昊商雪祝慧李昕玺徐会圃. PI3K/AKT信号通路在心血管疾病中的研究进展 [J]. 国际医药卫生导报, 2023, 29(15): 2077-2080.
[9]	董金玉龚星源马跃胡忠波刘晟刘永良. 二甲双胍在脊髓损伤中的实验性研究进展 [J]. 国际医药卫生导报, 2023, 29(15): 2081-2085.
[10]	孙虓刘成霞王娜郝佳慧储琳琳. 电针刺激治疗败血症及其相关疾病的研究进展 [J]. 国际医药卫生导报, 2023, 29(15): 2086-2090.
[11]	刘瀛张磊磊. 凶险性前置胎盘诊治进展 [J]. 国际医药卫生导报, 2023, 29(15): 2091-2095.
[12]	陈嘉瑶陈诗雁欧阳良艳祝志敏陈菲邱少东. 斑点追踪技术在评估主动脉瓣狭窄患者左心室功能中的临床应用价值 [J]. 国际医药卫生导报, 2023, 29(14): 1936-1939.
[13]	徐萌邢绍强祝兴旺张学峰王世鹏. 上尿路尿路上皮癌根治术后膀胱内复发的危险因素及膀胱灌注的研究进展 [J]. 国际医药卫生导报, 2023, 29(14): 1944-1949.
[14]	周鸿明李云逸李伟龙宋卓恒陈宇曹锐胡波栾韶东尹良红. 机器学习在血液透析治疗中的应用进展 [J]. 国际医药卫生导报, 2023, 29(13): 1777-1781.
[15]	周建国符大勇王蕴丹. 无创性影像技术在缺血性脑卒中血脑屏障通透性评估方面的应用进展 [J]. 国际医药卫生导报, 2023, 29(13): 1786-1789.